PALO ALTO, Calif.--(BUSINESS WIRE)--StemCells, Inc. (NASDAQ: STEM) today announced that the first transplantation of the Company’s proprietary human neural stem cell product—HuCNS-SC™— took place yesterday at the Oregon Health & Science University’s (OHSU) Doernbecher Children’s Hospital. This transplant is the first of six that are planned as part of the Company’s Phase I clinical trial designed to evaluate the safety and preliminary efficacy of HuCNS-SC as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL). NCL, which is often referred to as Batten disease, is a rare and fatal neurodegenerative condition afflicting infants and children.
